Sagimet Biosciences (NASDAQ:SGMT), Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small molecule therapies for metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s lead candidate, SGMT-05, is an orally administered agent in development to reduce liver fat accumulation and fibrosis through a multifaceted mechanism targeting key pathways implicated in NASH. In parallel, Sagimet maintains a preclinical pipeline that includes compounds aimed at addressing dyslipidemia and cardiometabolic risk factors, leveraging proprietary medicinal chemistry platforms to optimize pharmacokinetic and safety profiles.
Founded in 2014, Sagimet is headquartered in the United States and has established research collaborations and partnerships across North America, Europe and Asia. The company operates state‐of‐the‐art laboratory facilities and works closely with contract research organizations and academic institutions to accelerate its translational and clinical research programs. Over the years, Sagimet has secured non‐dilutive funding and strategic alliances to support its scientific agenda and expand its global footprint in metabolic disease research.
The Sagimet leadership team is composed of seasoned executives with deep experience in biotechnology, pharmaceutical development and regulatory affairs. Led by a chief executive officer with over two decades of drug development expertise, the senior management team guides the company’s strategy from early discovery through clinical proof of concept. Sagimet’s board of directors includes industry veterans who have held leadership roles at major biopharmaceutical firms, providing governance and strategic insight to drive the company’s mission.
With a mission to address the significant unmet medical need in NASH and related metabolic disorders, Sagimet Biosciences is positioned to advance its innovative small molecule pipeline through clinical development and regulatory milestones. By combining scientific rigor with strategic partnerships, the company aims to deliver safe and effective therapies that improve patient outcomes and set new standards in metabolic disease treatment.
